MDA-7/IL-24 Expression and Its Relation with Clinicopathologic Factors in Lung Adenocarcinomas of 3 cm or Less in Diameter.
- Author:
Mee Sook ROH
1
;
Phil Jo CHOI
;
Choonhee SON
;
Soo Keol LEE
Author Information
- Publication Type:Original Article
- Keywords: Interleukin-24; Adenocarcinoma; Lung; Immunohistochemistry
- MeSH: Adenocarcinoma; Apoptosis; Humans; Immunohistochemistry; Interleukins; Lung; Lung Neoplasms; Lymph Nodes; Melanoma; Neoplasm Metastasis; Population Characteristics; Prognosis
- From:Journal of Lung Cancer 2012;11(2):71-76
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The melanoma differentiation-associated gene-7 (MDA-7) protein, also known as interleukin 24 (IL-24), is a novel candidate of tumor suppressor that has been found to experimentally induce apoptosis and growth inhibition in a variety of human malignant cells. However, there have been few studies about its role in lung adenocarcinoma. Even at the same stage and with similar pathologic characteristics, lung adenocarcinomas with a diameter of 3 cm or less can have a variable prognosis depending on their biologic characteristics. The purpose of this study is to define the relationship between MDA-7/IL-24 expression and the progression of small-sized lung adenocarcinomas. MATERIALS AND METHODS: We performed immunohistochemical detection of MDA-7/IL-24 in forty-seven tissue samples from primary lung adenocarcinomas of < or =3 cm in diameter by using tissue microarray. RESULTS: MDA-7/IL-24 immunoreactivity was observed in 20 (42.6%) of the 47 adenocarcinoma cases. MDA-7/IL-24 expression was positive in 66.7% of the adenocarcinomas < or =2 cm, and in 31.3% of the adenocarcinomas >2 cm or < or =3 cm in diameter. A statistically significant association was found between MDA-7/IL-24 expression and tumor size (p=0.03). Although this difference did not reach statistical significance, tumors with a negative MDA-7/IL-24 expression tended to more frequently show lymph node metastasis (p=0.07). There were no significant associations for other clinicopathologic characteristics. CONCLUSION: These results suggest the possible involvement of MDA-7/IL-24 in the growth and progression of small-sized lung adenocarcinoma. MDA-7/IL-24 immunoreactivity could be used to identify a subset of adenocarcinomas of the lung of 3 cm or less in diameter that have different biologic behavior.
